Pacific GeneTech develops and commercializes next-generation vaccines and biologics targeting areas of high unmet need. Our vaccines, initially created for veterinary applications, use "Aegis", a proprietary technology platform enabling broad-spectrum protection across related pathogens. They can be administered orally or by injection in both live and inactivated forms. All our inactivated vaccines incorporate our "Hercules" adjuvant delivery system.
We target the intestinal bacteria Salmonella, E. coli, Campylobacter and Shigella; parasites such as Eimeria, Toxoplasma, and Cryptosporidium; and viruses such as Influenza A. Poultry vaccines for Salmonella and Eimeria are in the USDA’s regulatory process and submissions for Salmonella in pigs and Toxoplasma in ruminants are planned. Collaborations for human dysentery are in place.
Pacific GeneTech identifies high value discovery-stage opportunities through collaborations with leading research institutions and companies.
Our in-house R&D team takes high value research discoveries out of the laboratory, through the development and regulatory process, to the market (commercialization). In addition to the Aegis and Hercules platforms, PGT is working with partners to bring other technologies into our development process.
Commercialization is effected through out-licensing partnerships with the necessary expertise to manufacture and distribute products globally. Pacific GeneTech partners with multi-national and strong regional companies to commercialize these products, and has a joint venture in SE Asia which manufactures and distributes Hercules adjuvant delivery system.